Sponsors & Clinical research organizations
If you’re looking for sites with a diverse patient population, outstanding research staff, and the most up-to-date technology, look no further! Centex Studies has 5 locations across Texas and Louisiana, including the most diverse city in the world, Houston, and the Latino hubs, McAllen & Brownsville. That unique patient access combined with our fully dedicated research staff and industry-leading technology is what really sets Centex Studies above the competition! Keep reading to find out if we could be the perfect fit for your study.
OUR SPECIALTIES & REFERRAL NETWORK
Equipment & Facilities
Each of our facilities is a dedicated research site. From vent hoods to Fibroscans, and everything in between, we've got your technology needs covered!
eSource & eRegulatory
eSource & eRegulatory enables us to have the most accurate data as fast as possible. It also has remote monitoring capabilities. Meaning less travel for your CRA!
Marketing CRM Platform
We're nothing without our patients and our database! We have the technological capability to effectively nurture our database, keep up with all leads, and provide accurate ROI reporting.
TOP PERFORMANCE METRICS
Top Performing NASH Study
This phase 3 study was evaluating a new drug for the treatment of Liver Fibrosis in patients with Nonalcoholic Steatohepatitis.
Challenges in this study included the need for liver biopsies and the fibrosis level of the inclusion criteria.
To combat these challenges, we offered free FibroScans to our local community and partnered with local GIs for pre-qualified referrals.
Top Performing Low Back Pain Study
This phase 3 study was evaluating a new drug for relief of Low Back Pain.
Challenges for this study included the overwhelming amount of interest received to participate, and weeding out the noncompliant subjects.
To combat these challenges, we had a training with our recruitment staff and put a very thorough pre-screening process in place.
Top Performing Osteoarthritis Study
This phase 3 study was evaluating a new drug for hip and knee pain caused by Osteoarthritis.
Challenges for this study included the patient having too much pain relief, thus performing actions they should not have and injuring themselves.
To combat this challenge, we disclosed the information to the sponsor and informed patients prior to enrollment that even if they feel better, their arthritis is still there and could still progress.